Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral tetra-arsenic tetra-sulphide formula plus ATRA versus intravenous arsenic trioxide plus ATRA in newly diagnosed non-high-risk acute promyelocytic leukemia
ChiCTR-TRC-13004054Phase 3Completed
- Sponsor
- Peking University People's Hospital
- Start
- Jan 2014
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of arsenic tetrasulfide, tretinoin and arsenic trioxide in Acute promyelocytic leukaemia (APL) (2 arms), sponsored by Peking University People's Hospital. Primary endpoints: Event-free survival rate and Cumulative incidence of relapse. Started Jan 2014; status: completed.
02
Drugs
arsenic tetrasulfidetretinoinarsenic trioxide
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR-TRC-13004054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13004054.